Core Viewpoint - Jinbo Bio is leveraging its first-mover advantage and original innovation capabilities to establish a "license barrier" in the industry, aiming to become a world-class technology-driven bio-materials enterprise amidst increasing competition [2]. Group 1: Product Development and Innovation - Jinbo Bio has made significant breakthroughs with its core products, including the first international discovery and analysis of the atomic structure of type III collagen, which features a flexible helical structure at 164.88° [3]. - The company has developed the first original bio-material with independent intellectual property rights in China, including a broad-spectrum anti-HPV bio-protein and a multi-peptide drug for COVID-19 [3][4]. - Jinbo Bio holds three class III medical device registration certificates for recombinant human collagen, covering all dosage forms including freeze-dried fibers, solutions, and gels [3][7]. Group 2: Research and Development - The company has completed 12 projects on the atomic structure of human collagen, aiming to develop more innovative and differentiated products [4]. - Jinbo Bio has developed the "AI Collagen Brain System" to enhance research efficiency and reliability, collaborating with several universities and research institutions to establish research platforms [5]. Group 3: Industry Standards and Market Position - Jinbo Bio has participated in the formulation of multiple industry standards and is expanding into international standards, enhancing its influence in the global biopharmaceutical field [6]. - The company has maintained a leading position in the recombinant human collagen sector, despite increased competition, by leveraging its established clinical data and distribution networks [7]. Group 4: Strategic Development and Future Plans - Jinbo Bio is constructing a recombinant human collagen industrial park in collaboration with the Shanxi Comprehensive Reform Demonstration Zone to attract upstream and downstream enterprises [8]. - The company plans to enhance its product matrix and distribution channels, focusing on innovative product development and expanding market coverage through partnerships and brand promotion [8][9]. - Jinbo Bio aims to become an internationally leading bio-materials enterprise by deepening basic research and applying new technologies in the healthcare sector [9].

Core Insights - The 2025 BIO-Europe conference was held in Vienna, Austria, from November 3 to 5, showcasing the advancements in biopharmaceuticals and precision medicine from Shanxi Province [3][4] - The Shanxi delegation, organized by the China Council for the Promotion of International Trade Shanxi Committee, included key pharmaceutical companies that aimed to enhance international collaboration and showcase their innovations [3][4] Company Highlights - Shanxi Shuangyan Pharmaceutical Co., Ltd. promoted its high-end active pharmaceutical ingredients and formulations, certified by FDA and EDQM, with exports to over 50 countries [4] - Shanxi Zhendong Pharmaceutical Co., Ltd. showcased its achievements in the modernization of traditional Chinese medicine and functional health foods [4] - Shanxi Naan Biotechnology Co., Ltd. introduced its self-developed Bio-Lattix technology platform and innovative drug pipelines, including ADCs and RDCs [4] - Taiyuan Huarui Qiyuan Technology Co., Ltd. presented the world's first commercial standing CT and diagnostic reagent culture device, attracting attention from medical and investment institutions [4] - Shanxi Jinbo Biopharmaceutical Co., Ltd. displayed its proprietary human-derived collagen new materials and broad-spectrum antiviral bioproducts, highlighting its leading green manufacturing technology [4] - Shanxi Yellow River Traditional Chinese Medicine Co., Ltd. showcased its 300-year-old brand "Yishengtang," emphasizing the integration of traditional Chinese medicine culture with modern research [4] Industry Collaboration - The Shanxi delegation engaged in in-depth discussions with various European biopharmaceutical companies, research institutions, and investment funds during the conference [4] - The delegation leader, Wang Xiu, emphasized the importance of this event in promoting Shanxi pharmaceutical companies to expand into international markets and enhance the global influence of the "Shanxi brand" [4]